Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing TrialsLisha Mou, Zuhui Pu, Xiaohe Tian et al.|Frontiers in Oncology|2021Cited by 74
Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomesYan Zhang, Hai Li, Wenting Tan et al.|Journal of Hepatology|2023Cited by 53
LncRNAs Target Ferroptosis-Related Genes and Impair Activation of CD4+ T Cell in Gastric CancerFuwen Yao, Lisha Mou, Yongqiang Zhan et al.|Frontiers in Cell and Developmental Biology|2021Cited by 50
Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled studyYu Song, Junping Shi, Wenjing Ni et al.|Cell Reports Medicine|2025Cited by 29
LBP-045 Efficacy and safety of HSK31679, a thyroid hormone receptor β agonist, for the treatment of asian non-alcoholic fatty liver disease: a multicenter randomized, double-blind, placebo-controlled, phase 2a trialXue Feng, Lai Wei, Wei Ma et al.|Journal of Hepatology|2024Cited by 27